JP2017502985A - 修飾シクロデキストリン複合体をカプセル化するリポソーム組成物およびその使用 - Google Patents

修飾シクロデキストリン複合体をカプセル化するリポソーム組成物およびその使用 Download PDF

Info

Publication number
JP2017502985A
JP2017502985A JP2016546484A JP2016546484A JP2017502985A JP 2017502985 A JP2017502985 A JP 2017502985A JP 2016546484 A JP2016546484 A JP 2016546484A JP 2016546484 A JP2016546484 A JP 2016546484A JP 2017502985 A JP2017502985 A JP 2017502985A
Authority
JP
Japan
Prior art keywords
cyclodextrin
liposome
liposomes
liposome composition
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016546484A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017502985A5 (enExample
Inventor
バート フォーゲルシュタイン，
バート フォーゲルシュタイン，
ケネス ダブリュー． キンズラー，
ケネス ダブリュー． キンズラー，
シビン ゾウ，
シビン ゾウ，
スロジット スル，
スロジット スル，
Original Assignee
ザ・ジョンズ・ホプキンス・ユニバーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・ジョンズ・ホプキンス・ユニバーシティー filed Critical ザ・ジョンズ・ホプキンス・ユニバーシティー
Publication of JP2017502985A publication Critical patent/JP2017502985A/ja
Publication of JP2017502985A5 publication Critical patent/JP2017502985A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016546484A 2014-01-14 2015-01-14 修飾シクロデキストリン複合体をカプセル化するリポソーム組成物およびその使用 Pending JP2017502985A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461927233P 2014-01-14 2014-01-14
US61/927,233 2014-01-14
PCT/US2015/011342 WO2015108932A1 (en) 2014-01-14 2015-01-14 Liposome compositions encapsulating modified cyclodextrin complexes and uses thereof

Publications (2)

Publication Number Publication Date
JP2017502985A true JP2017502985A (ja) 2017-01-26
JP2017502985A5 JP2017502985A5 (enExample) 2018-02-22

Family

ID=53543384

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016546484A Pending JP2017502985A (ja) 2014-01-14 2015-01-14 修飾シクロデキストリン複合体をカプセル化するリポソーム組成物およびその使用

Country Status (8)

Country Link
US (2) US20180161274A1 (enExample)
EP (1) EP3094313A4 (enExample)
JP (1) JP2017502985A (enExample)
CN (1) CN106659683A (enExample)
AU (1) AU2015206628A1 (enExample)
CA (1) CA2936963A1 (enExample)
HK (1) HK1231397A1 (enExample)
WO (1) WO2015108932A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020505451A (ja) * 2017-01-18 2020-02-20 テマセク・ライフ・サイエンシーズ・ラボラトリー・リミテッドＴｅｍａｓｅｋ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌａｂｏｒａｔｏｒｙ Ｌｉｍｉｔｅｄ 超安定リポソームによる有糸分裂細胞の標的化の増加

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3370712B1 (en) 2015-11-06 2025-02-19 The Johns Hopkins University 3-bromopyruvate for treating liver fibrosis
CN108478533B (zh) * 2018-04-23 2020-12-08 滨州医学院 β环糊精-LPC脂质体制备方法及其作为药物载体的应用
CN112384226B (zh) * 2018-07-06 2024-06-28 丸大食品株式会社 含有缩醛磷脂的组合物
CN108853111B (zh) * 2018-08-07 2020-06-05 浙江大学 一种组合物在制备治疗吉非替尼肝脏毒性药物中的应用
CN111449187B (zh) * 2020-05-09 2022-10-14 扬州大学 一种布氏乳杆菌S-层蛋白修饰的香芹酚/β-环糊精脂质体及其制备方法和抗菌用途
EP4026945A1 (en) * 2021-01-07 2022-07-13 Calik Denim Tekstil San. Ve Tic. A.S. Encapsulated indigo
CN114113426B (zh) * 2021-12-27 2024-04-26 西安血氧生物技术有限公司 一种血红蛋白氧载体中磷脂的检测方法
CN115386262B (zh) * 2022-09-26 2023-05-12 杭州海维特化工科技有限公司 一种应用于汽车内饰装饰塑料膜的缓释香精和负离子的凹印水墨及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04500229A (ja) * 1988-08-31 1992-01-16 オーストレイリアン・コマーシヤル・リサーチ・アンド・デイベロツプメント・リミテツド 薬剤分配用及びクロマトグラフィー用の組成物及び方法
JPH08509230A (ja) * 1993-04-22 1996-10-01 デポテック コーポレイション 医薬化合物を被包しているシクロデキストリンリポソーム及びその使用法
WO2012118376A1 (en) * 2011-03-01 2012-09-07 To-Bbb Holding B.V. Advanced active liposomal loading of poorly water-soluble substances
JP2013508313A (ja) * 2009-10-26 2013-03-07 石葯集団中奇制葯技▲術▼（石家庄）有限公司 スルホブチルエーテルシクロデキストリン塩を含有する内水相を有するリポソーム
JP2013540824A (ja) * 2010-10-28 2013-11-07 パシラ ファーマシューティカルズ インコーポレーテッド 非ステロイド性抗炎症薬の徐放性処方物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2036504A6 (es) * 1990-03-02 1993-05-16 Australian Commercial Research Procedimiento para preparar complejos de ciclodextrina.
HU213200B (en) * 1993-05-12 1997-03-28 Chinoin Gyogyszer Es Vegyeszet The cyclodextrin or cyclodextrin derivative cluster complexes of taxol, taxotere, or taxus, pharmaceutical preparations containing them and process for their production
DE19814815C2 (de) * 1998-04-02 2000-10-12 Gerhard Steffan Sterinverknüpfte, anionische Cyclodextrinderivate und deren Verwendung in Arzneimittelformulierungen
CN1813679A (zh) * 2005-11-30 2006-08-09 上海医药(集团)有限公司 一种紫杉烷脂质体冻干组合物及其制备方法
CN101653414B (zh) * 2008-08-19 2011-07-20 中国科学院上海药物研究所 多西他赛长循环固体脂质纳米粒及其制备方法
EP2415464B1 (en) * 2009-03-30 2017-05-10 Eisai R&D Management Co., Ltd. Method for producing liposome composition
CN102397248A (zh) * 2010-09-15 2012-04-04 万物(北京)医药科技发展有限公司 一种辛二酰苯胺异羟肟酸环糊精包合物脂质体
WO2014004651A1 (en) * 2012-06-26 2014-01-03 The Johns Hopkins University Multifunctional tunable biomaterials for tissue engineering
WO2014121235A2 (en) * 2013-02-01 2014-08-07 Zoneone Pharma, Inc. Transformation of drug cyclodextrin complex compositions into compositions of mixtures of lipid vesicle encapsulated drug and cyclodextrin drug complexes

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04500229A (ja) * 1988-08-31 1992-01-16 オーストレイリアン・コマーシヤル・リサーチ・アンド・デイベロツプメント・リミテツド 薬剤分配用及びクロマトグラフィー用の組成物及び方法
JPH08509230A (ja) * 1993-04-22 1996-10-01 デポテック コーポレイション 医薬化合物を被包しているシクロデキストリンリポソーム及びその使用法
JP2013508313A (ja) * 2009-10-26 2013-03-07 石葯集団中奇制葯技▲術▼（石家庄）有限公司 スルホブチルエーテルシクロデキストリン塩を含有する内水相を有するリポソーム
JP2013540824A (ja) * 2010-10-28 2013-11-07 パシラ ファーマシューティカルズ インコーポレーテッド 非ステロイド性抗炎症薬の徐放性処方物
WO2012118376A1 (en) * 2011-03-01 2012-09-07 To-Bbb Holding B.V. Advanced active liposomal loading of poorly water-soluble substances

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020505451A (ja) * 2017-01-18 2020-02-20 テマセク・ライフ・サイエンシーズ・ラボラトリー・リミテッドＴｅｍａｓｅｋ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌａｂｏｒａｔｏｒｙ Ｌｉｍｉｔｅｄ 超安定リポソームによる有糸分裂細胞の標的化の増加
JP7232530B2 (ja) 2017-01-18 2023-03-03 テマセク・ライフ・サイエンシーズ・ラボラトリー・リミテッド 超安定リポソームによる有糸分裂細胞の標的化の増加

Also Published As

Publication number Publication date
HK1231397A1 (zh) 2017-12-22
AU2015206628A1 (en) 2016-08-25
US20180161274A1 (en) 2018-06-14
WO2015108932A1 (en) 2015-07-23
EP3094313A4 (en) 2017-07-12
EP3094313A1 (en) 2016-11-23
CN106659683A (zh) 2017-05-10
US20190328665A1 (en) 2019-10-31
CA2936963A1 (en) 2015-07-23

Similar Documents

Publication Publication Date Title
US20190328665A1 (en) Liposome compositions encapsulating modified cyclodextrin complexes and uses thereof
Chen et al. Nanobowl-supported liposomes improve drug loading and delivery
EP3787607B1 (en) Carotenoid compositions and uses thereof
Jadhav et al. Novel vesicular system: an overview
Çağdaş et al. Liposomes as Potential Drug Carrier Systems for Drug
JP2022003102A (ja) 異なる医薬品の制御送達のためのビヒクル
JP6894423B2 (ja) 融合性リポソーム被覆多孔質ケイ素ナノ粒子
JP5770336B2 (ja) リポソーム組成物の製造方法
KR100889139B1 (ko) 이리노테칸 제제
Liu et al. Effective co-encapsulation of doxorubicin and irinotecan for synergistic therapy using liposomes prepared with triethylammonium sucrose octasulfate as drug trapping agent
JP2009507049A (ja) リン脂質のポリエチレングリコール誘導体に包み込まれたビンカアルカロイド系制癌剤のナノミセル製剤
Qian et al. Pharmacokinetics and disposition of various drug loaded liposomes
CN117897140A (zh) 用于制备脂质体制剂的方法
JP2025026896A (ja) リポソームドキソルビシン製剤、リポソームドキソルビシン製剤の製造方法、および薬剤としてのリポソームドキソルビシン製剤の使用
JP4791067B2 (ja) リポソーム製剤の製造方法
JP2020521004A (ja) ｃ（ＲＧＤ−ＡＣＰ−Ｋ）修飾血中滞留型リポソーム
US10925831B2 (en) Liposomal formulations of platinum-acridine anticancer agents and methods thereof
WO2022124898A1 (en) Auristatin-loaded liposomes and uses thereof.
AU2020364256A1 (en) Delivery system complexes comprising a precipitate of an active agent and methods of use
JP2011211996A (ja) 腫瘍特異性を有するリポソーム
Messerer Liposomal encapsulation of irinotecan and potential for the use of liposomal drug in the treatment of liver metastases associated with advanced colorectal cancer
Abishek et al. Optimization and troubleshooting, limitations, future opportunities for improvement in liposomes drug delivery technologies
KR100768265B1 (ko) 혈액내 순환시간을 향상시키기 위한 헤파린이 수식된리포솜 및 이의 제조방법
WO2025184543A1 (en) Compositions and methods for delivery of therapeutic compounds
Liu Development of novel drug delivery systems for cancer therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180112

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180928

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181024

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190118

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190322

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190701